spironolactone has been researched along with Apoplexy in 17 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Further, this is the first study demonstrating amiloride could also improve myocardial fibrosis." | 9.17 | Myocardial fibrosis and QTc are reduced following treatment with spironolactone or amiloride in stroke survivors: a randomised placebo-controlled cross-over trial. ( MacWalter, RS; McSwiggan, S; Ogston, SA; Struthers, AD; Sze, KY; Wong, KY; Wong, SY, 2013) |
| " Spironolactone, a mineralocorticoid receptor antagonist, decreases ischemic cerebral infarct size in male spontaneously hypertensive stroke-prone rats (SHRSP)." | 7.74 | Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone rats. ( Dorrance, AM; Pollock, DM; Rigsby, CS, 2007) |
| " The antistroke effects of captopril treatment occurred without an antihypertensive effect, weren't altered by enhancing hypertension during treatment (with dexamethasone), and couldn't be duplicated by antihypertensive treatment with hydralazine." | 7.70 | Effect of poststroke captopril treatment on mortality associated with hemorrhagic stroke in stroke-prone rats. ( King, SR; Smeda, J; Vasdev, S, 1999) |
| "Aldosterone is a risk factor for stroke, and the literature suggests it may play a role in increasing the expression of the receptor for EGF (EGFR)." | 5.31 | Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. ( Dorrance, AM; Grekin, R; Osborn, HL; Webb, RC, 2001) |
| " Further, this is the first study demonstrating amiloride could also improve myocardial fibrosis." | 5.17 | Myocardial fibrosis and QTc are reduced following treatment with spironolactone or amiloride in stroke survivors: a randomised placebo-controlled cross-over trial. ( MacWalter, RS; McSwiggan, S; Ogston, SA; Struthers, AD; Sze, KY; Wong, KY; Wong, SY, 2013) |
| " Spironolactone, a mineralocorticoid receptor antagonist, decreases ischemic cerebral infarct size in male spontaneously hypertensive stroke-prone rats (SHRSP)." | 3.74 | Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone rats. ( Dorrance, AM; Pollock, DM; Rigsby, CS, 2007) |
| " Previous studies from our laboratory have shown that chronic treatment with spironolactone, a mineralocorticoid receptor (MR) antagonist, decreases ischemic cerebral infarct size and prevents remodeling of the middle cerebral artery (MCA) in male spontaneously hypertensive stroke-prone rats (SHRSP)." | 3.74 | Intact female stroke-prone hypertensive rats lack responsiveness to mineralocorticoid receptor antagonists. ( Burch, AE; Dorrance, AM; Ogbi, S; Pollock, DM; Rigsby, CS, 2007) |
| " The antistroke effects of captopril treatment occurred without an antihypertensive effect, weren't altered by enhancing hypertension during treatment (with dexamethasone), and couldn't be duplicated by antihypertensive treatment with hydralazine." | 3.70 | Effect of poststroke captopril treatment on mortality associated with hemorrhagic stroke in stroke-prone rats. ( King, SR; Smeda, J; Vasdev, S, 1999) |
| "Additionally, ischemic heart disease adversely impacts the clinical course of HFrEF patients; however, its role in HFpEF is not fully understood." | 3.01 | Role of Ischemic Heart Disease in Major Adverse Renal and Cardiac Events Among Individuals With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial). ( Elsaid, O; McCullough, PA; Rahimi, G; Tecson, KM, 2021) |
| "Aldosterone is a risk factor for stroke, and the literature suggests it may play a role in increasing the expression of the receptor for EGF (EGFR)." | 1.31 | Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. ( Dorrance, AM; Grekin, R; Osborn, HL; Webb, RC, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, W | 1 |
| Wu, Y | 1 |
| Zhou, Y | 1 |
| Liang, W | 1 |
| Xue, R | 1 |
| Wu, Z | 1 |
| Dong, Y | 1 |
| Liu, C | 1 |
| Rahimi, G | 1 |
| Tecson, KM | 1 |
| Elsaid, O | 1 |
| McCullough, PA | 1 |
| O'Neal, WT | 2 |
| Sandesara, P | 1 |
| Hammadah, M | 2 |
| Venkatesh, S | 1 |
| Samman-Tahhan, A | 2 |
| Kelli, HM | 2 |
| Soliman, EZ | 1 |
| Sandesara, PB | 1 |
| Tsujimoto, T | 1 |
| Kajio, H | 1 |
| Wong, KY | 1 |
| Wong, SY | 1 |
| McSwiggan, S | 1 |
| Ogston, SA | 1 |
| Sze, KY | 1 |
| MacWalter, RS | 1 |
| Struthers, AD | 1 |
| Moret, M | 1 |
| Darbellay, P | 1 |
| Lebowitz, D | 1 |
| Alves, C | 1 |
| Sabeh, N | 1 |
| Carballo, S | 1 |
| Dorrance, AM | 4 |
| de Peuter, OR | 1 |
| Lip, GY | 1 |
| Souverein, PC | 1 |
| Klungel, OH | 1 |
| de Boer, A | 1 |
| Büller, HR | 1 |
| Kamphuisen, PW | 1 |
| Nakagaki, T | 1 |
| Hirooka, Y | 2 |
| Matsukawa, R | 2 |
| Nishihara, M | 1 |
| Nakano, M | 2 |
| Ito, K | 2 |
| Hoka, S | 1 |
| Sunagawa, K | 2 |
| Frieler, RA | 1 |
| Ray, JJ | 1 |
| Meng, H | 1 |
| Ramnarayanan, SP | 1 |
| Usher, MG | 1 |
| Su, EJ | 1 |
| Berger, S | 1 |
| Pinsky, DJ | 1 |
| Lawrence, DA | 1 |
| Wang, MM | 1 |
| Mortensen, RM | 1 |
| Rigsby, CS | 2 |
| Pollock, DM | 2 |
| Burch, AE | 1 |
| Ogbi, S | 1 |
| Smeda, J | 1 |
| Vasdev, S | 1 |
| King, SR | 1 |
| Osborn, HL | 1 |
| Grekin, R | 1 |
| Webb, RC | 1 |
| Naruse, M | 1 |
| Tanabe, A | 1 |
| Sato, A | 1 |
| Takagi, S | 1 |
| Tsuchiya, K | 1 |
| Imaki, T | 1 |
| Takano, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)[NCT00094302] | Phase 3 | 3,445 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
First incidence of aborted cardiac arrest (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.09 |
| Spironolactone | 0.05 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 4.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 3.1 |
| Spironolactone | 2.8 |
Hospitalization for MI, stroke or the management of heart failure, whichever occurred first (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.2 |
| Spironolactone | 5.5 |
Average post-baseline Chloride, taking into consideration baseline Chloride, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 102.33 |
| Spironolactone | 102.26 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 7.8 |
| Spironolactone | 7.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.6 |
| Spironolactone | 5.9 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
"Average post-baseline depression, taking into consideration baseline depression, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Patient Health Questionnaire (PHQ) is a 10-item, self-administered instrument for screening, diagnosing, monitoring and measuring the severity of depression. Scores can range from 0-27, in which lower scores reflect better mental health status. The PH-Q was administered at the following study visits: baseline, month 12 and annually thereafter. Valid translations of this questionnaire were only available for subjects enrolled in the United States and Canada." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 5.6 |
| Spironolactone | 5.1 |
First incidence of a deterioration of renal function. The TOPCAT protocol defines deterioration of renal function as occurring if a subject has a serum creatinine value which is at least double the baseline value for that subject, and is also above the upper limit of normal (assumed to be 1.0 mg/dL for females and 1.2 mg/dL for males.) (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 2.2 |
| Spironolactone | 3.2 |
First incidence of atrial fibrillation among subjects without a history of atrial fibrillation at baseline (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.4 |
| Spironolactone | 1.4 |
Average post-baseline GFR, taking into consideration baseline GFR, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mL/min/1.73m2 (Least Squares Mean) |
|---|---|
| Placebo | 67.50 |
| Spironolactone | 65.20 |
First incidence of a hospitalization for any reason (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 20.0 |
| Spironolactone | 18.8 |
First incidence of a hospitalization for the management of heart failure (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 3.8 |
First incidence of myocardial infarction (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.2 |
First incidence of new onset diabetes mellitus among subjects without a history of diabetes mellitus at baseline. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.7 |
| Spironolactone | 0.7 |
Average post-baseline Potassium, taking into consideration baseline Potassium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 4.32 |
| Spironolactone | 4.49 |
"Average post-baseline quality of life, taking into consideration baseline quality of life and treatment group.~The McMaster Overall Treatment Evaluation questionnaire is a self-administered 3-item instrument that measures a patient's perception of change in their health-related quality of life since the start of therapy. The questionnaire consists of a single question - Since treatment started, has there been any change in your activity limitation, symptoms and/or feelings related to your heart condition? Scores can range from -7 to +7, and higher scores reflect better health status. The questionnaire was administered at the following study visits: month 4 and month 12. Valid translations of this questionnaire were only available for subjects enrolled in the United States, Canada and Argentina." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.2 |
| Spironolactone | 1.2 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The EuroQOL visual analog scale (EQ5D) is a single-item, self-administered instrument that quantifies current health status. Scores can range from 0-100, in which higher scores reflect better health status. The EQ5D was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 65.9 |
| Spironolactone | 66.4 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. The KCCQ was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 63.1 |
| Spironolactone | 64.4 |
Average post-baseline serum creatinine, taking into consideration baseline serum creatinine, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 1.11 |
| Spironolactone | 1.17 |
Average post-baseline Sodium, taking into consideration baseline Sodium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 140.95 |
| Spironolactone | 140.33 |
First incidence of stroke (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 8.3 |
| Spironolactone | 6.8 |
4 trials available for spironolactone and Apoplexy
| Article | Year |
|---|---|
Role of Ischemic Heart Disease in Major Adverse Renal and Cardiac Events Among Individuals With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial).
Topics: Aged; Cardiovascular Diseases; Case-Control Studies; Creatinine; Diabetes Mellitus; Disease Progress | 2021 |
Gender Differences in the Risk of Adverse Outcomes in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiograph | 2017 |
Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction.
Topics: Aged; Cause of Death; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Miner | 2017 |
Myocardial fibrosis and QTc are reduced following treatment with spironolactone or amiloride in stroke survivors: a randomised placebo-controlled cross-over trial.
Topics: Aged; Amiloride; Cross-Over Studies; Diuretics; Double-Blind Method; Female; Fibrosis; Heart Disease | 2013 |
13 other studies available for spironolactone and Apoplexy
| Article | Year |
|---|---|
CHA2DS2-VASc and ATRIA Scores and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction.
Topics: Aged; Aged, 80 and over; Cause of Death; Clinical Trials, Phase III as Topic; Decision Support Techn | 2020 |
Use of Nitrates and Risk of Cardiovascular Events in Patients With Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarc | 2019 |
[Internal medicine in the hospital setting].
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Asymptomatic Diseases | 2015 |
Stroke therapy: is spironolactone the Holy Grail?
Topics: Humans; Mineralocorticoid Receptor Antagonists; Neuroprotective Agents; Receptors, Mineralocorticoid | 2008 |
Time-trends in treatment and cardiovascular events in patients with heart failure: a pharmacosurveillance study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angina Pectoris; Angiotensin-Converting Enzyme | 2011 |
Activation of mineralocorticoid receptors in the rostral ventrolateral medulla is involved in hypertensive mechanisms in stroke-prone spontaneously hypertensive rats.
Topics: Aldosterone; Animals; Blood Pressure; Eplerenone; Hypertension; Male; Medulla Oblongata; Microinject | 2012 |
Mineralocorticoid receptors/epithelial Na(+) channels in the choroid plexus are involved in hypertensive mechanisms in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Choroid Plexus; Disease Models, Animal; Epithelial Sodium Channels; Epleren | 2013 |
Myeloid mineralocorticoid receptor during experimental ischemic stroke: effects of model and sex.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Eplerenone; Female; Gene Expression Profiling; Immu | 2012 |
Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone rats.
Topics: Animals; Blood Pressure; Cerebrovascular Circulation; Compliance; Disease Models, Animal; Dose-Respo | 2007 |
Intact female stroke-prone hypertensive rats lack responsiveness to mineralocorticoid receptor antagonists.
Topics: Animals; Brain Ischemia; Cerebral Arteries; Eplerenone; Female; Male; Mineralocorticoid Receptor Ant | 2007 |
Effect of poststroke captopril treatment on mortality associated with hemorrhagic stroke in stroke-prone rats.
Topics: Aldosterone; Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Blood Pressure; Captopril; | 1999 |
Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats.
Topics: Aldosterone; Animals; Aorta; Basal Ganglia; Blood Pressure; Body Weight; Cerebral Cortex; Cerebral I | 2001 |
Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats.
Topics: Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Animals; | 2002 |